Considerations for Moderna's move to get an EUA for the COVID-19 vaccine in young kids

Video

Editorial board member Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN, discusses the recently release topline data, the potential timeline, and what potential stumbling blocks could be.

Editorial board member Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN, discusses the recently release topline data, the potential timeline, and what potential stumbling blocks could be.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!
Recent Videos
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Jennifer Soung, MD reacts to FDA approval of roflumilast foam 0.3%
Suzanne Hollander, MS, RD, LDN, Senior Clinical Nutrition Specialist, Boston Children's Hospital | Image credit: Boston Children's
Russell Libby, MD, FAAP
Lawrence Eichenfield, MD
Related Content
FDA approves gardenia blue as natural color additive for food use | Image credit: Contemporary Pediatrics

FDA approves gardenia blue as natural color additive for food use

Morgan Ebert, Managing Editor
July 14th 2025
Article

The FDA approves gardenia (genipin) blue as a natural food color, enhancing options for manufacturers and supporting the shift away from synthetic dyes.

FDA-approved berdazimer gel, 10.3% launches to treat molluscum contagiosum | Image Credit: © syahrir - ©syahrir - stock.adobe.com.

FDA-approved berdazimer gel, 10.3% launches to treat molluscum contagiosum

Joshua Fitch, Senior Editor
July 10th 2025
Article

The nitric oxide–releasing topical is the first prescription medication approved for at-home treatment of molluscum contagiosum.

FDA accepts NDA for ET-600, desmopressin oral solution for pediatric AVP deficiency | © Contemporary Pediatrics

FDA accepts NDA for ET-600, desmopressin oral solution for pediatric AVP deficiency

Morgan Ebert, Managing Editor
July 8th 2025
Article

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.

FDA approves sebetralstat as first and only on-demand treatment for HAE | Image Credit: Contemporary Pediatrics

FDA approves sebetralstat as first and only on-demand treatment for HAE

Joshua Fitch, Senior Editor
July 7th 2025
Article

Though the original target action date was not met by the FDA, KalVista's sebetralstat is now approved to treat HAE in patients 12 years and older.

Key FDA approvals in pediatric health: First half of 2025 | Image Credit: © Postmodern Studio - stock.adobe.com.

Key FDA approvals in pediatric health: First half of 2025

Morgan Ebert, Managing Editor
July 5th 2025
Article

A roundup of the most impactful FDA approvals in pediatric health from January through June 2025, spanning diagnostics, therapeutics, and at-home care.

© Contemporary Pediatrics

FDA news in pediatrics: June 2025

Morgan Ebert, Managing Editor
July 1st 2025
Article

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from June 2025.

© 2025 MJH Life Sciences

All rights reserved.